ClinicalTrials.gg
CompletedNCT03944109Updated Nov 30, 2022

The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia

A Phase 1/2 interventional study of SHR-1209 and Placebo in Hyperlipidemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-11-30.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 1 of them phase 3. Hyperlipidemias · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
6th of 14
110 · median 78
Started
2019
the only one that year
Phase 1/2
Only one
of the 14
Registered
1st of 14
by date

Among the 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd., this one is the 6th largest by enrollment, is the only one that started in 2019, is the only one in phase 1/2, and was the 1st registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

3 of the 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo- controlled phaseⅠb/Ⅱclinical study. Totally 108 subjects are planned to enrolled with 36 subjects in three low-dose groups (group 1, group 2 and group 3) and 72 subjects in three high-dose groups (group 4, group 5, and group 6).12 subjects with hyperlipidemia who received statin stable treatment for more than 28 days are enrolled in each low-dose group, randomly given SHR-1209 or placebo treatment at a ratio of 5:1. 24 subjects with hyperlipidemia who received statin stable treatment for more than 28 days are enrolled in each high-dose group, randomly given SHR-1209 or placebo treatment at a ratio of 5:1. The primary objective of this study is to evaluate the safety, tolerability, and efficacy of multiple subcutaneous injections of SHR-1209 in hyperlipidemia subjects treated with stabilized dose of statin. Groups detail as follows:

  1. SHR-1209 dose 1 /placebo frequence 1
  2. SHR-1209 dose 2 /placebo frequence 2
  3. SHR-1209 dose 3 /placebo frequence 3
  4. SHR-1209 dose 4 /placebo frequence 1
  5. SHR-1209 dose 5 /placebo frequence 2
  6. SHR-1209 dose 6 /placebo frequence 3
03

Conditions studied

  • Hyperlipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 and ≤65 years old;
  2. Subjects who are receiving statin therapy at the time of screening or who are eligible for statin therapy can randomized to receive a stable dose of statin therapy for more than 28 days and are willing to maintain stable statin therapy in this study;
  3. Low-density lipoprotein cholesterol (LDL-C) level ≥2.6mmol/L of subjects who receiving statin and/or other lipid-lowering therapy at the time of screening, or LDL-C≥ 3.4mmol/L of subjects who didn't receive any-lowering therapy at the time of screening, and LDL-C still ≥2.6mmol/L before randomization;
  4. Fasting triglycerides ≤4.5 mmol/L;
  5. (BMI) ≥18 and ≤ 35 kg/m2;
  6. Signed .

Exclusion criteria

Exclusion Criteria:

  1. A clinical history of drug allergy or a history of atopic allergic diseases (asthma, urticaria, eczema dermatitis) or a known allergy to experimental or similar experimental drugs;
  2. Diagnosis of homozygous familial hypercholesterolemia;
  3. (NYHA) defined Ⅱ - Ⅳ history of heart failure;
  4. History of acute coronary syndrome (e.g. myocardial infarction, hospitalization for unstable angina), or percutaneous coronary intervention, or coronary artery bypass graft, or history of cerebrovascular disease, within 12 months prior to screening;
  5. Uncontrolled severe arrhythmias that are not controlled by drugs or other therapy within 12 months prior to enrollment;
  6. Uncontrolled hypertension (systolic blood pressure ≥ 160 and/or diastolic blood pressure ≥ 100 mmHg);
  7. (ALT) or aspartate aminotransferase (AST) or gamma pancreatic acyl transferase (GGT), more than 2.5x ;
  8. Subjects with previous malignant tumor diseases. etc.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    SHR-1209

    Participants received one of 6 dose levels of SHR-1209 administered as multiple subcutaneous doses.

    Drug: SHR-1209

  • Placebo comparator
    Placebo

    Participants received matching placebo dose regimens by subcutaneous injection.

    Drug: Placebo

Interventions

  • Pharmaceutical form: lyophilized formulation Route of administration: subcutaneous

  • DrugPlacebo

    Pharmaceutical form: lyophilized formulation Route of administration: subcutaneous

06

What researchers measure

Primary outcomes

  1. Primary efficacy end point:Percent change from baseline to end of the dosing interval in LDL-C.

    Time frame: Baseline to day 113 for group1,2,4,5 or day 169 for group 3,6

  2. Primary safety end point:Number of subjects with adverse events.

    Time frame: Baseline to day 169 for group 1,3,4,6 or day 141 for group 2,5

Secondary outcomes

  1. Absolute change from baseline to end of the dosing interval in LDL-C.

    Time frame: Baseline to day 113 for group1,2,4,5 or day 169 for group 3,6

  2. Percent change from baseline to day 85 in LDL-C.

    Time frame: Baseline to day 85 for all 6 groups

  3. Absolute change from baseline to day 85 in LDL-C.

    Time frame: Baseline to day 85 for all 6 groups

  4. Percent change in PCSK9.

    Time frame: Baseline to day 169 for group 1,3,4,6 or day 141 for group 2,5

  5. Absolute change in PCSK9.

    Time frame: Baseline to day 169 for group 1,3,4,6 or day 141 for group 2,5

07

Study locations

1 site
  • Sun Yat-Sen Memorial Hospital ,The Second Affiliated Hospital of Sun Yat-Sen University
    Guangzhou, Guangdong, China
08

References and documents

Publications

  • Xu M, Zhu X, Wu J, Zhang Y, Zhao D, Wang X, Ding Y, Cao Y, Li C, Hu W, Sheng J, Luo Z, Zheng Z, Hu J, Liu J, Zhou X, Shen A, Ding X, Zhang Y, Zhao Y, Li Y, Zhong S, An S, Zou J, Yan L. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study. BMC Med. 2022 Jan 18;20(1):13. doi: 10.1186/s12916-021-02208-w. PubMed 35039035 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Dec 2020, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2019
First posted
May 9, 2019
StartActual
Jun 20, 2019
Primary completionActual
Dec 22, 2020
CompletionActual
Dec 22, 2020
Last update
Nov 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03944109
Responsible party
Sponsor
First posted
May 9, 2019
Start date
Jun 20, 2019
Primary completion
Dec 22, 2020
Completion
Dec 22, 2020
Last update
Nov 30, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recaticimab

Start the discussion